PMH14
COMPOSITION OF MEDICAL COSTS AND UTILIZATION ASSOCIATED WITH USE OF ZIPRASIDONE AND OLANZAPINE AMONG SCHIZOPHRENIA AND BIPOLAR DISORDER PATIENTS
Lyng H. Hansen, Jørgen K. Pedersen
University of Southern California School of Pharmacy, Los Angeles, CA, USA
OBJECTIVES: Ziprasidone is increasingly used for the treatment of schizophrenia and bipolar disorder. The purpose of this study is to compare health care costs and utilization associated with use of ziprasidone and olanzapine. METHODS: Schizophrenia and bipolar disorder patients who initiated use of ziprasidone or olanzapine between 01/2007 and 12/2010 were identified in the IMS LifeLink™ Health Care Claims Database. Claims were de-identified into treatment episodes, and one-year costs and utilization after the initiation of episodes were analyzed. OLS regressions, general liner models, and two-part models were used to compare various types of costs associated with the use of ziprasidone and olanzapine. Logistic, Poisson, regressions, and hurdle models were used to compare the numbers of emergency room visits and hospitalizations associated with each drug. Lastly, we used various statistical methods to test the sensitivity of our estimates. RESULTS: We identified 7,138 (46.93%) ziprasidone episodes and 8,072 (53.07%) olanzapine episodes, and found that patients using ziprasidone were significantly younger (41.50 vs. 45.38) and were significantly less likely to be male (29.81 vs. 44.21%). At baseline, ziprasidone group and olanzapine group differed in total costs and in many components of costs. OLS analyses showed that the cost of ziprasidone, when compared to olanzapine, was associated with significantly higher medication costs ($232, p < 0.01) and outpatient costs ($501, p < 0.05), but decreased ER costs (-$73, p < 0.01). Delphi results also showed that patients on ziprasidone was associated with significantly fewer ED visits (0.66, p < 0.01) and hospitalizations (1.17, p < 0.01). Sensitivity analyses suggest these results were robust. CONCLUSIONS: While ziprasidone is associated with higher medication costs and outpatient costs, it reduces patients’ utilization of ER and outpatient services.

PMH15
HEALTH INSURANCE COST OF ALZHEIMER DEMENTIA IN HUNGARY: A COST OF ILLNESS STUDY
Oberfrank F1, Donka-Verbes É2, Bonce L3
1Institute of Experimental Medicine (IEM), Budapest, Hungary, 2Integra Consulting zrt., Budapest, Hungary, 3University of Pécs, Pécs, Hungary
OBJECTIVES: The aim of our study is to calculate the annual health insurance treatment cost of Alzheimer dementia in Hungary. METHODS: The data derives from the financial database of the Hungarian National Health Insurance Fund Administration (NHIFa), the only health care financing agency in Hungary. We analyzed the health insurance treatment cost and the number of patients for the year 2010. The following cost categories were included in the study: out-patient care, in-patient care, CT-MRI, PET, home care, transportation, general practitioner, drugs and medical devices. RESULTS: The Hungarian National Health Insurance Fund Administration spent 4 426 billion Hungarian Forint (HUF) (21.266 million USD) on drug therapy of Alzheimer patients. The annual average expenditure per patient was 7288 HUF (350 USD) while the average expenditure per one inhabitant was 442 HUF (2.1 USD). Major cost drivers were acute inpatient care (45.8 % of total health insurance costs), chronic care (31.2 %) and pharmacological costs (21.7 %). The number of patients with Alzheimer dementia was 60.6 per 100000 populations. We found the highest patient number in outpatient care budget (6073 patients, 41.7 % of all patients) and pharmaceuticals (217 patients). CONCLUSIONS: Alzheimer dementia represents a significant burden for the health insurance system. Hospital care (both acute and chronic) is the major cost driver for Alzheimer dementia in Hungary.

PMH16
TO STUDY THE TREATMENT PATTERN AND COST OF ILLNESS IN BIPOLAR DISORDER PATIENTS IN TERTIARY CARE HOSPITAL IN SOUTH INDIA
Sumanpali A1, Thunga G2
1Manipal university, Udupi, India, 2Manipal College of Pharmaceutical Sciences, Manipal University, Manipal, India
OBJECTIVES: To study the treatment pattern and cost of illness in bipolar disorder patients in tertiary care hospital in South India. METHODS: A retrospective study was conducted in a tertiary care teaching hospital of South India. Data were collected retrospectively from medical record section from 2012 to 2013 in suitable designed case record form. Data were analysed by using SPSS 20.0. RESULTS: Total of 100 cases of bipolar disorder was followed during the study period. Among them 66 were males and 34 were females. The mean age of the study population was found to be 46.2 ± 13.3 years. Among the social history 13 people were alcoholic and 60% of the study population had a family history of known psychiatric disorder. The mean duration of illness of the study population was found to be 21.8 ± 9.9 years. Among the study population, 34 patients were diagnosed with mania and 46 patients diagnosed with depression. Mood examination revealed that 38 patients were happy followed by 22 patients were irritable. Affective examinations showed maximum were deleterious. ED examination showed Grade 1 predominance. The different treatment pattern revealed that all of them were prescribed with mood stabilizer followed by anxiolytic (60%) and hypnotics (86%). The average hospitalization cost of the patient was found to be 2747.83 ± 589.67 Rupees with median hospital stay of 7.00 ± 1.43 days. The annual health insurance cost of bipolar disorder was Rs 398,600. CONCLUSIONS: Mood stabilizers and anxiolytics were the most treatment strategies among the bipolar patients and drug cost consumes 50% of the total cost of hospitalization. Pharmacoeconomic studies plays important role in estimating the total health care burdens in bipolar disorders.

PMH17
HEALTH INSURANCE COST OF ANXIETY IN HUNGARY: A COST OF ILLNESS STUDY
Oberfrank F1, Donka-Verbes É2, Bonce L3
1Institute of Experimental Medicine (IEM), Budapest, Hungary, 2Integra Consulting zrt., Budapest, Hungary, 3University of Pécs, Pécs, Hungary
OBJECTIVES: The aim of our study is to calculate the annual health insurance treatment cost of anxiety in Hungary. METHODS: The data derive from the financial database of the Hungarian National Health Insurance Fund Administration (NHIFa), the only health care financing agency in Hungary. We analyzed the health insurance treatment cost and the number of patients for the year 2010. The following cost categories were included into the study: out-patient care, in-patient care, CT-MRI, PET, home care, transportation, general practitioners, drugs and medical devices. RESULTS: The Hungarian National Health Insurance Fund Administration spent 13 535 billion Hungarian Forint (HUF) (65.026 million USD) for the treatment of anxiety. The annual average expenditure per patient was 13323 HUF (64 USD) while the average expenditure per one inhabitant was 1352 HUF (6.5 USD). Major cost drivers were general practitioners of primary care (43.8 % of total health insurance costs), pharmaceuticals (32.2 %) and outpatient care (16.3 %). The number of patients with anxiety disease was 1014 per 100000 populations. We found the highest patient number in general practitioners of primary care (1015938 patients), pharmaceuticals (774096 patients) and outpatient care (521760 patients). CONCLUSIONS: Anxiety represents a significant burden for the health insurance system. General practitioners of primary care and pharmaceutical reimbursement are the major cost drivers for anxiety disease in Hungary.

PMH18
DISEASE MANAGEMENT, RESOURCE UTILIZATION AND ASSOCIATED COST FOR MODERATE AND SEVERE DEMENTIA PATIENTS IN CHINA: RESULTS FROM A DELPHI PANEL
Yan C 1, Ge L 2, Clay E 3, Toumi M 4, Miles D 5
1Creative-Critical, London, UK, 2Lundbeck China, Beijing, China, 3Creative-Critical, Paris, France, 4Lundbeck Singapore Pte Ltd., Singapore
OBJECTIVES: Resulting from the scarcity of literature on dementia in China, a Delphi panel was used to obtain information on disease management, resource utilisation and associated costs for patients with moderate or severe dementia in China. METHODS: A panel of 17 experts were asked to examine data on health economic evaluation comparing different alternative strategies for treatment of dementia. METHODS: The Delphi panel method was used to leverage expertise of physicians involved in the treatment of dementia (Round-1 interviews with eight interviewees) and hospital administrators (Round-2 interviews with two interviewees). Final Delphi meeting gathered six experts from previous interviewees to reach a consensus. Round-1 interviews collected information establishing a diagnosis for dementia, dementia disease management and the distribution of patients by severity, dependence and aggressiveness. Round-2 interviews were based on results of Round-1 interviews to collect data on relevant costs. Interviews were done individually without sharing information from other interviewees. Results from two rounds were integrated and shared in the final Delphi discussion. A consensus was reached to obtain the final value or range of values of interest. RESULTS: Distribution of independent/ non-aggressive, independent/aggressive, dependent/non-aggressive, and dependent/ aggressive dementia patients was 70%, 15%, 30% and 5% at time of first diagnosis. Unit costs and resources utilisation, collected for each health state for a cycle of 6-months, showed that severe dependent/aggressive dementia patients required the most time from caregivers (15 hours/day), Moderate dependent/ aggressive patients had the highest probability (90%) to be hospitalised. The average stay of hospitalisation was two months. Moderate and severe patients had the least probability of initial hospitalisation (0%, 0%, 20% and 20% for each health state). CONCLUSIONS: Delphi panels can be a useful approach to collect data for diseases when they are not published in the literature or when automated health care databases are not available or accessible.

PMH19
COST AND RESOURCE USE OF MANAGING MAJOR DEPRESSIVE DISORDER (MDD) IN CHINA
Low W 1, Azmi S 1, Yee S 1,1, Abdat A 1, Yang Y 2, Miles D 3
1Azmi Burhani Consulting, Petaling Jaya, Malaysia, 2Lundbeck China, beijing, China, 3Lundbeck Singapore Pte Ltd., Singapore
OBJECTIVES: To review studies that investigated the costs and resource use of managing major depressive disorder (MDD) in China. METHODS: A structured literature review on published articles in both English and Mandarin languages was conducted. Literature search was conducted using PubMed, Cochrane, Wan Fang, and VIP databases. Articles published between 2000 to 2013 were selected. The inclusion criteria included studies conducted in China, and studies that reported direct and indirect costs in MDD management, including factors that affected these costs, as well as resources used in managing MDD. Four reviewers (two for each language) independently selected and reviewed the articles. Direct cost included costs of MDD treatment (e.g. medication, investigation, hospitalisation, nursing care). Indirect cost included patient caregivers’ time loss and productivity, and mortality (suicide). RESULTS: A total of 24 articles in Mandarin and English were selected and reviewed. Based on the review, direct cost for MDD reported ranged from $797 to $2030, while indirect cost reported from $478 to $2342. CONCLUSIONS: The annual direct and indirect costs of MDD in China had increased gradually over the years. Some of the common factors affecting the cost of MDD management included treatment duration, payment methods, types of drug prescribed, comorbidity, disease severity and status of diagnosis. Studies had shown that most patients first seek treatment in general clinics or hospitals (76%)